Biocogniv
Biocogniv is an innovative company focused on AI-based diagnostics for acute care, aiming to reduce preventable hospital deaths and improve patient outcomes. Their flagship product, Sepsis ai Marker™, utilizes routine laboratory tests to predict sepsis up to 72 hours in advance, significantly enhancing early detection and intervention. With over 16 million patient encounters and 1 billion lab results analyzed, Biocogniv leverages large clinical databases and advanced AI models to provide real-world evidence and insights, positioning itself as a leader in the healthcare technology space. The company has achieved FDA Breakthrough Designation for its product and maintains ISO 13485:2016 certification, underscoring its commitment to regulatory excellence and innovation in medical diagnostics.
Biocogniv
Biocogniv is an innovative company focused on AI-based diagnostics for acute care, aiming to reduce preventable hospital deaths and improve patient outcomes. Their flagship product, Sepsis ai Marker™, utilizes routine laboratory tests to predict sepsis up to 72 hours in advance, significantly enhancing early detection and intervention. With over 16 million patient encounters and 1 billion lab results analyzed, Biocogniv leverages large clinical databases and advanced AI models to provide real-world evidence and insights, positioning itself as a leader in the healthcare technology space. The company has achieved FDA Breakthrough Designation for its product and maintains ISO 13485:2016 certification, underscoring its commitment to regulatory excellence and innovation in medical diagnostics.